Finance

Lists
Outlook: 65.2% bullish·0.0% bearish
Go to analysis
ABT:NYSE
Abbott Laboratories
US$ ९८.४९
-०.२४%
(-०.२४) 1D
US$ ९८.४९
०.००% (०.००)
After hours
Closed: अक्टोबर ८, १६:०२:३८ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ABT...
Open
US$ ९८.५६
High
US$ ९९.२०
Low
US$ ९७.२०
Mkt. cap
१.७० खरब
Avg. vol.
८७.७२ लाख
Volume
१.३९ करोड
Dividend
२.५६%
Quarterly dividend
US$ ०.६३
Ex-dividend date
२०२६ अक्टोबर १५
P/E ratio
३१.७०
52-wk high
US$ १३५.१२
52-wk low
US$ ८१.९७
EPS
US$ ३.११
Beta
०.५९
Shares outstanding
१.७३ अरब
No. of employees
१ लाख
Open
US$ ९८.५६
High
US$ ९९.२०
Low
US$ ९७.२०
Mkt. cap
१.७० खरब
Avg. vol.
८७.७२ लाख
Volume
१.३९ करोड
Dividend
२.५६%
Quarterly dividend
US$ ०.६३
Ex-dividend date
२०२६ अक्टोबर १५
P/E ratio
३१.७०
52-wk high
US$ १३५.१२
52-wk low
US$ ८१.९७
EPS
US$ ३.११
Beta
०.५९
Shares outstanding
१.७३ अरब
No. of employees
१ लाख
News stories
From web sources and news partners
Profile
Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company founded in Chicago with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices. Abbott operates in over 160 countries and sources from at least 62 suppliers worldwide. Abbott's products include Pedialyte, Similac, BinaxNOW, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT and MitraClip. The company is ranked 107th on the Fortune 500 and 144th on the Forbes Global 2000. Wikipedia
About Abbott Laboratories
CEORobert B. Ford
Employees१.१५ लाख
Founded१८८८
Headquartersशिकागो, इलिनोइ, संयुक्त राज्य अमेरिका
Sector-
Websiteabbott.com
Analyst ratings
Based on 14 analysts giving stock ratings to ABT in the past 3 months
Strong buy
Buy
14
Hold
0
Sell
0
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for ABT in the last 3 months.
Highest
Current US$ ९८.४९
US$ १३५.०० (+३७.०७%)
Average
US$ १२५.५० (+२७.४२%)
Lowest
US$ ११२.०० (+१३.७२%)
Analyst
Recommendation
Action
Price target
Projected
Date
Matt Miksic
Barclays
Buy
Maintained
US$ १२०.००
+२१.८%
10/07/2026
Himanshu Patel
J.P. Morgan
Buy
Initiated
US$ १२०.००
+२१.८%
10/07/2026
Larry Biegelsen
Wells Fargo
Buy
Maintained
US$ ११२.००
+१३.७%
10/05/2026
Joanne Wuensch
Citi
Buy
Maintained
US$ १२५.००
+२६.९%
10/05/2026
Travis Steed
Bank of America Securities
Buy
Maintained
US$ ११५.००
+१६.८%
10/01/2026
Ed Ridley-Day
Rothschild & Co Redburn
Buy
Upgraded
US$ १२७.००
+२८.९%
10/02/2026
Kendall Au
RBC Capital
Buy
Maintained
US$ १३०.००
+३२%
10/01/2026
Josh Jennings
TD Cowen
Buy
Reiterated
US$ १३५.००
+३७.१%
09/14/2026
Robbie Marcus
J.P. Morgan
Buy
Maintained
-
-
09/01/2026
Adam Maeder
Piper Sandler
Buy
Maintained
US$ ११८.००
+१९.८%
08/26/2026
Matthew Taylor
Jefferies
Buy
Reiterated
US$ १३५.००
+३७.१%
08/21/2026
Marie Thibault
BTIG
Buy
Maintained
US$ १३४.००
+३६.१%
08/20/2026
Brandon Vazquez
William Blair
Buy
Maintained
-
-
08/21/2026
Michael Polark
Wolfe Research
Buy
Upgraded
US$ १३०.००
+३२%
08/13/2026
Danielle Antalffy
UBS
Buy
Reiterated
US$ १२५.००
+२६.९%
07/28/2026
Patrick Wood
UBS
Buy
Reiterated
US$ १२५.००
+२६.९%
07/28/2026
Unknown Analyst
Jefferies
Buy
Reiterated
US$ १३५.००
+३७.१%
07/17/2026
Shagun Singh Chadha
RBC Capital
Buy
Reiterated
US$ १३०.००
+३२%
07/16/2026
Jayson Bedford
Raymond James
Buy
Maintained
-
-
07/17/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
US$ ११२.००
+१३.७%
07/06/2026
David Rescott
Robert W. Baird
Buy
Initiated
US$ १२१.००
+२२.९%
06/30/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
US$ ११०.००
+११.७%
06/29/2026
David Roman
Goldman Sachs
Buy
Maintained
US$ ११३.००
+१४.७%
05/31/2026
Narumi Nakagiri
Daiwa
Hold
Downgraded
US$ ९२.००
-६.६%
04/21/2026
Anthony Petrone
Mizuho Securities
Hold
Maintained
US$ ११५.००
+१६.८%
04/20/2026
Suraj Kalia
Oppenheimer
Buy
Maintained
US$ ११५.००
+१६.८%
04/17/2026
Bruce Jackson
Benchmark Co.
Buy
Maintained
US$ १२०.००
+२१.८%
04/17/2026
Rick Wise
Stifel Nicolaus
Buy
Reiterated
US$ १२०.००
+२१.८%
04/17/2026
Unknown Analyst
Goldman Sachs
Buy
Reiterated
US$ १२१.००
+२२.९%
04/09/2026
Unknown Analyst
Erste Group
Hold
Maintained
-
-
04/01/2026
Next call १३ दिनमा
अक्टोबर २१, बुध, १५:००
Fiscal period
Q3 2026
EPS / Est. (USD)
- / US$ १.४२
Revenue / Est. (USD)
- / १२.९९ अरब
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
११.३७ अरब
११.४६ अरब
११.१६ अरब
१२.५९ अरब
Cost of goods sold
५.०८ अरब
४.९१ अरब
४.८९ अरब
५.३२ अरब
Cost of revenue
५.०८ अरब
४.९१ अरब
४.८९ अरब
५.३२ अरब
Research and development expenses
७६.६० करोड
७२.०० करोड
७६.७० करोड
८९.२० करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
२.९० अरब
२.९३ अरब
३.५८ अरब
३.८७ अरब
Operating expense
४.०९ अरब
४.०७ अरब
४.७७ अरब
५.४२ अरब
Total operating expenses
९.१६ अरब
८.९८ अरब
९.६६ अरब
१०.७४ अरब
Operating income
२.२० अरब
२.४८ अरब
१.५० अरब
१.८५ अरब
Other non operating income
२०.०० लाख
-१.५० करोड
-
-२.५० करोड
EBT including unusual items
२.१८ अरब
२.३६ अरब
१.४५ अरब
१.५२ अरब
EBT excluding unusual items
२.१८ अरब
२.४४ अरब
१.४५ अरब
१.५२ अरब
Income tax expense
५३.६० करोड
५८.२० करोड
३७.२० करोड
५९.६० करोड
Effective tax rate
२४.५९%
२४.६८%
२५.६७%
३९.११%
Other operating expenses
-
-
-
-
Net income
१.६४ अरब
१.७८ अरब
१.०८ अरब
९२.८० करोड
Net profit margin
१४.४६%
१५.५०%
९.६५%
७.३७%
Earnings per share
१.३०
१.५०
१.१५
१.३१
Interest and investment income
७.७० करोड
७.८० करोड
१०.६० करोड
५.२० करोड
Interest expense
-१२.१० करोड
-१२.०० करोड
-१७.४० करोड
-३५.१० करोड
Net interest expenses
-४.४० करोड
-४.२० करोड
-६.८० करोड
-२९.९० करोड
Depreciation and amortization charges
-
-
-
-
EBITDA
३.०० अरब
३.२७ अरब
२.३१ अरब
२.९१ अरब
Gain or loss from assets sale
-
६.५० करोड
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google एपहरू